{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:12:01Z","timestamp":1787163121146,"version":"build-2736575974"},"reference-count":30,"publisher":"China Science Publishing & Media Ltd.","issue":"3","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.3724\/abbs.2025135","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:19:14Z","timestamp":1753697954000},"page":"574-583","update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Targeting USP2 induces degradation of PML-RAR\u03b1 with or without drug-resistant mutations in acute promyelocytic leukemia"],"prefix":"10.3724","volume":"58","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenge","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2026","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","volume":"32","author":"de Th\u00e9 H","year":"2017","unstructured":"de Th\u00e9 H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell, 2017, 32: 552-560.","journal-title":"Cancer Cell"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ccr.2005.01.005","volume":"7","author":"Zhu J","year":"2005","unstructured":"Zhu J, Zhou J, Peres L, Riaucoux F, Honor\u00e9 N, Kogan S, de Th\u00e9 H. A sumoylation site in PML\/RARA is essential for leukemic transformation. Cancer Cell, 2005, 7: 143-153.","journal-title":"Cancer Cell"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/cdd.2016.111","volume":"24","author":"Chen ZH","year":"2017","unstructured":"Chen ZH, Wang WT, Huang W, Fang K, Sun YM, Liu SR, Luo XQ. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway. Cell Death Differ, 2017, 24: 212-224.","journal-title":"Cell Death Differ"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","volume":"35","author":"Platzbecker U","year":"2017","unstructured":"Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized italian-german APL0406 trial. J Clin Oncol, 2017, 35: 605-612.","journal-title":"J Clin Oncol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"Kantarjian HM","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin, 2025, 75: 46-67.","journal-title":"CA Cancer J Clin"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","volume":"11","author":"Yilmaz M","year":"2021","unstructured":"Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J, 2021, 11: 123.","journal-title":"Blood Cancer J"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ccr.2010.06.003","volume":"18","author":"Jeanne M","year":"2010","unstructured":"Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, Peres L. PML\/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell, 2010, 18: 88-98.","journal-title":"Cancer Cell"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1126\/science.1183424","volume":"328","author":"Zhang XW","year":"2010","unstructured":"Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX. Arsenic trioxide controls the fate of the PML-RAR\u03b1 oncoprotein by directly binding PML. Science, 2010, 328: 240-243.","journal-title":"Science"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/leu.2016.69","volume":"30","author":"Madan V","year":"2016","unstructured":"Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J, Kanojia D. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30: 1672-1681.","journal-title":"Leukemia"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1182\/blood-2015-04-637678","volume":"127","author":"Liu J","year":"2016","unstructured":"Liu J, Zhu HH, Jiang H, Jiang Q, Huang XJ. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. Blood, 2016, 127: 243-250.","journal-title":"Blood"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood-2011-01-329433","volume":"118","author":"Goto E","year":"2011","unstructured":"Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, 2011, 118: 1600-1609.","journal-title":"Blood"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"5726","DOI":"10.1038\/s41467-022-33147-6","volume":"13","author":"Tessier S","year":"2022","unstructured":"Tessier S, Ferhi O, Geoffroy MC, Gonz\u00e1lez-Prieto R, Canat A, Quentin S, Pla M. Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells. Nat Commun, 2022, 13: 5726.","journal-title":"Nat Commun"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3390\/cancers11101591","volume":"11","author":"Noguera N","year":"2019","unstructured":"Noguera N, Catalano G, Banella C, Divona M, Faraoni I, Ottone T, Arcese W. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers, 2019, 11: 1591.","journal-title":"Cancers"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1182\/blood.V92.4.1172","volume":"92","author":"Ding W","year":"1998","unstructured":"Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood, 1998, 92: 1172-1183.","journal-title":"Blood"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood-2012-01-407601","volume":"120","author":"Gallagher RE","year":"2012","unstructured":"Gallagher RE, Moser BK, Racevskis J, Poir\u00e9 X, Bloomfield CD, Carroll AJ, Ketterling RP. Treatment-influenced associations of PML-RAR\u03b1 mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood, 2012, 120: 2098-2108.","journal-title":"Blood"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41418-023-01139-8","volume":"30","author":"Dai B","year":"2023","unstructured":"Dai B, Wang F, Wang Y, Zhu J, Li Y, Zhang T, Zhao L. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RAR\u03b1. Cell Death Differ, 2023, 30: 1320-1333.","journal-title":"Cell Death Differ"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"Harrigan JA","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov, 2018, 17: 57-78.","journal-title":"Nat Rev Drug Discov"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.apsb.2021.10.020","volume":"12","author":"Shao X","year":"2022","unstructured":"Shao X, Chen Y, Wang W, Du W, Zhang X, Cai M, Bing S. Blockade of deubiquitinase YOD1 degrades oncogenic PML\/RAR\u03b1 and eradicates acute promyelocytic leukemia cells. Acta Pharm Sin B, 2022, 12: 1856-1870.","journal-title":"Acta Pharm Sin B"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"24628","DOI":"10.1074\/jbc.M116.738567","volume":"291","author":"Davis MI","year":"2016","unstructured":"Davis MI, Pragani R, Fox JT, Shen M, Parmar K, Gaudiano EF, Liu L. Small molecule inhibition of the ubiquitin-specific protease USP2 accelerates cyclin D1 degradation and leads to cell cycle arrest in colorectal cancer and mantle cell lymphoma models. J Biol Chem, 2016, 291: 24628-24640.","journal-title":"J Biol Chem"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1038\/onc.2012.537","volume":"32","author":"Yang WC","year":"2013","unstructured":"Yang WC, Shih HM. The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF\/RARA stability. Oncogene, 2013, 32: 5167-5175.","journal-title":"Oncogene"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1038\/sj.leu.2402720","volume":"16","author":"Redner RL","year":"2002","unstructured":"Redner RL. Variations on a theme: the alternate translocations in APL. Leukemia, 2002, 16: 1927-1932.","journal-title":"Leukemia"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/ng0298-126","volume":"18","author":"He LZ","year":"1998","unstructured":"He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP. Distinct interactions of PML-RAR\u03b1 and PLZF-RAR\u03b1 with co-repressors determine differential responses to RA in APL. Nat Genet, 1998, 18: 126-135.","journal-title":"Nat Genet"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","volume":"30","author":"Kuang Z","year":"2023","unstructured":"Kuang Z, Liu X, Zhang N, Dong J, Sun C, Yin M, Wang Y. USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1. Cell Death Differ, 2023, 30: 2249-2264.","journal-title":"Cell Death Differ"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41419-024-07168-6","volume":"15","author":"Wang S","year":"2024","unstructured":"Wang S, Nie J, Jiang H, Li A, Zhong N, Tong W, Yao G. VCP enhances autophagy-related osteosarcoma progression by recruiting USP2 to inhibit ubiquitination and degradation of FASN. Cell Death Dis, 2024, 15: 788.","journal-title":"Cell Death Dis"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1080\/15548627.2022.2044651","volume":"18","author":"Xiao W","year":"2022","unstructured":"Xiao W, Wang J, Wang X, Cai S, Guo Y, Ye L, Li D. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression. Autophagy, 2022, 18: 2615-2635.","journal-title":"Autophagy"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3892\/or.2023.8613","volume":"50","author":"Zhang S","year":"2023","unstructured":"Zhang S, Guo Y, Zhang S, Wang Z, Zhang Y, Zuo S. Targeting the deubiquitinase USP2 for malignant tumor therapy (Review). Oncol Rep, 2023, 50: 176.","journal-title":"Oncol Rep"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1038\/s41418-020-0538-8","volume":"27","author":"Zhang J","year":"2020","unstructured":"Zhang J, Liu S, Li Q, Shi Y, Wu Y, Liu F, Wang S. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ, 2020, 27: 2710-2725.","journal-title":"Cell Death Differ"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"116275","DOI":"10.1016\/j.ejmech.2024.116275","volume":"268","author":"Tian Y","year":"2024","unstructured":"Tian Y, Liu K, Wu D, Wu L, Xu Q, Wei W, Li Z. The discovery of potent USP2\/USP8 dual-target inhibitors for the treatment of breast cancer via structure guided optimization of ML364. Eur J Med Chem, 2024, 268: 116275.","journal-title":"Eur J Med Chem"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1016\/j.apsb.2024.08.019","volume":"14","author":"Wang Y","year":"2024","unstructured":"Wang Y, Zhang Y, Luo H, Wei W, Liu W, Wang W, Wu Y. Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells. Acta Pharm Sin B, 2024, 14: 5235-5248.","journal-title":"Acta Pharm Sin B"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/sj.emboj.7601567","volume":"26","author":"Stevenson LF","year":"2007","unstructured":"Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP, Saville MK. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J, 2007, 26: 976-986.","journal-title":"EMBO J"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/133E68C8ACD84F008A8A0C5DDF7D55D9","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025135","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciengine.com\/doi\/pdf\/133E68C8ACD84F008A8A0C5DDF7D55D9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:15:58Z","timestamp":1775204158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciengine.com\/doi\/10.3724\/abbs.2025135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.3724\/abbs.2025135","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.11.653221","asserted-by":"object"}]},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}